Across-cancer specific immune responses induced by nanovaccines or microvaccines to prevent different cancers and cancer metastasis
Lu Diao,
Lin Ma,
Junping Cheng,
Yunzhi Pan,
Zuofu Peng,
Lianjun Zhang,
Minghao Xu,
Yupei Li,
Xuenong Zhang,
Honglv Jiang,
Guoqiang Xu,
Fenghua Meng,
Zhiyuan Zhong,
Mi Liu
Affiliations
Lu Diao
Department of Pharmaceutics, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, People’s Republic of China; Suzhou Ersheng Biopharmaceutical Co., Ltd, Suzhou 215123, People’s Republic of China
Lin Ma
Department of Pharmaceutics, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, People’s Republic of China
Junping Cheng
The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou 215505, People’s Republic of China
Yunzhi Pan
The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou 215505, People’s Republic of China
Zuofu Peng
AlphaX (Beijing) Biotech Co., Ltd., Beijing 100083, People’s Republic of China
Lianjun Zhang
Institute of Systems Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China; Suzhou Institute of Systems Medicine, Suzhou 215123, China
Minghao Xu
The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou 215505, People’s Republic of China; Suzhou Ersheng Biopharmaceutical Co., Ltd, Suzhou 215123, People’s Republic of China
Yupei Li
Department of Pharmaceutics, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, People’s Republic of China
Xuenong Zhang
Department of Pharmaceutics, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, People’s Republic of China
Honglv Jiang
Department of Pharmaceutics, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, People’s Republic of China
Guoqiang Xu
Department of Pharmaceutics, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, People’s Republic of China
Fenghua Meng
Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, People’s Republic of China
Zhiyuan Zhong
Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, People’s Republic of China
Mi Liu
Department of Pharmaceutics, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, People’s Republic of China; Suzhou Ersheng Biopharmaceutical Co., Ltd, Suzhou 215123, People’s Republic of China; Corresponding author
Summary: Metastatic cancers and recurrent cancers are diverse, different from primary cancers, and organ-dependent. However, how strong are across-cancer immune responses among different types of cancers remain unclear. Herein, vaccines-encapsulated-whole-components-of-tumor-tissue (VEWCOTT) were applied to demonstrate the across-cancer immune responses, thanks to inducing pan-clones T-cell immune responses. Either lung-cancer-tissue- or melanoma-tissue-based VEWCOTT simultaneously prevented melanoma, lung cancer, hepatoma, and metastatic cancer, which showed that strong across-cancer immune responses were induced. Both nanovaccines and microvaccines showed potent across-cancer prevention efficacy. VEWCOTT induced tumor-specific T cells in peripheral immune organs and major organs, and adjusted the immune-microenvironment of cancer-colonized organs. In addition, the allograft of T cells from VEWCOTT immunized mice to allogeneic naive mice efficiently prevent various cancers. Many neoantigens are shared by melanoma cells and lung cancer cells. Across-cancer immune responses exist among different types of cancers, and thus VEWCOTT has the advantage of simultaneously preventing cancer metastasis and cancers in different organs.
